Newly added drugs in national reimbursement drug list vs First-in-class drug approvals in China
In 2025, newly added drugs in national reimbursement drug list in China stood at 114, against 11 for first-in-class drug approvals.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Newly added drugs in national reimbursement drug list and First-in-class drug approvals
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Newly added drugs in national reimbursement drug list | as of 7 Dec 2025 | Actual | 114 |
| Newly added drugs in national reimbursement drug list | as of 28 Nov 2024 | Actual | 91 |
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
Shared periods
Side by side
Only 2 periods are published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Newly added drugs in national reimbursement drug list
Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle.
2 observations in China · source organisations: NHSA, SCIO
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring